FBDD – Fragment Based Drug Discovery – A fast route for development of new drugs

Sprint Bioscience is a Drug Discovery company building a portfolio of innovative oncology projects, focusing on cancer metabolism.

With its highly efficient fragment based drug discovery platform, Sprint Bioscience can rapidly identify molecules with properties that are suitable for drug development. These molecules provide a firm basis for the drug discovery programs. In an iterative process that includes: protein science, fragment screening, medicinal chemistry, X-ray crystallography and relevant biology studies; Sprint Bioscience transform them into quality candidate drugs ready to enter the development process.

In addition, Sprint Bioscience offers via its subsidiary Gene2Lead™ full lead generation services including experienced project management.